News
Stay up to date with the latest from Marius Pharmaceuticals.
Latest In The News
What has been happening
Marius Pharmaceuticals Unveils New Corporate Website and Announces Longevity & Endocrinology Advisory Boards
February 21, 2025
Marius Pharmaceuticals Unveils New Corporate Website and Announces Longevity & Endocrinology Advisory Boards RALEIGH, N.C., (February 21, 2025) — Marius…Read more
Marius Pharmaceuticals Announces KYZATREX® (testosterone undecanoate) CIII Capsules Availability Through Thrive, Expanding Men’s Health Solutions
February 11, 2025
Marius Pharmaceuticals Announces KYZATREX® (testosterone undecanoate) CIII Capsules Availability Through Thrive, Expanding Men’s Health Solutions Raleigh, NC (February 11th, 2025)…Read more
Marius Pharmaceuticals Partners with US Specialists Management, LLC (“USSM”) Through Affiliated Urologic In-office Dispensaries
January 14, 2025
Marius Pharmaceuticals Partners with US Specialists Management, LLC (“USSM”) Through Affiliated Urologic In-office Dispensaries Raleigh, N.C., (January 14, 2025) – Marius Pharmaceuticals, a…Read more
KYZATREX® (Testosterone Undecanoate) CIII Capsules Expands Distribution Through New Collaboration with Gameday Men’s Health
December 3, 2024
KYZATREX® (Testosterone Undecanoate) CIII Capsules Expands Distribution Through New Collaboration with Gameday Men’s Health The Deal Gives Gameday Men’s Health…Read more
The Testosterone Project Launches on National Testosterone Awareness Day, November 17
November 15, 2024
The Testosterone Project Launches on National Testosterone Awareness Day, November 17 New Nonprofit Founded by Leading Testosterone Experts Seeks to…Read more
New Data from Marius Pharmaceuticals Reveals High Prevalence of Low Libido, Energy and Quality of Life in Men
November 14, 2024
New Data from Marius Pharmaceuticals Reveals High Prevalence of Low Libido, Energy and Quality of Life in Men RALEIGH, N.C.,…Read more
nuBioAge, nuHx and Marius Pharmaceuticals Team Up for Collaborative GLP-1 Comparison Study in Male Patients
September 25, 2024
nuBioAge, nuHx and Marius Pharmaceuticals Team Up for Collaborative GLP-1 Comparison Study in Male Patients WEST PALM BEACH, Fla., Sept.…Read more
Marius Pharmaceuticals Partners with UK-Based Numan to Combat Testosterone Deficiency with KYZATREX® (Testosterone Undecanoate) CIII Capsules
September 18, 2024
Marius Pharmaceuticals Partners with UK-Based Numan to Combat Testosterone Deficiency with KYZATREX® (Testosterone Undecanoate) CIII Capsules RALEIGH, N.C., September 18,…Read more
The Vitamin Shoppe® Expands its Whole Health Rx™ Telehealth Offering into Testosterone Replacement Therapy via a Partnership with Marius Pharmaceuticals for its KYZATREX® (Testosterone Undecanoate) CIII Capsules
September 3, 2024
The Vitamin Shoppe® Expands its Whole Health Rx™ Telehealth Offering into Testosterone Replacement Therapy via a Partnership with Marius Pharmaceuticals…Read more
Marius Pharmaceuticals Submits KYZATREX® (Testosterone Undecanoate) CIII Capsules for Approval to Health Canada
July 30, 2024
Marius Pharmaceuticals Submits KYZATREX® (Testosterone Undecanoate) CIII Capsules for Approval to Health Canada RALEIGH, N.C., July 30, 2024 — Marius…Read more
Marius Pharmaceuticals Announces Final Published Phase 3 Data from MRS-TU-2019EXT Studying the Safety and Efficacy of FDA-Approved KYZATREX® (testosterone undecanoate) CIII Capsules
April 11, 2024
Marius Pharmaceuticals Announces Final Published Phase 3 Data from MRS-TU-2019EXT Studying the Safety and Efficacy of FDA-Approved KYZATREX® (testosterone undecanoate)…Read more
Marius Pharmaceuticals Announces Pilot Study Exploring the Effect of its Oral Testosterone Therapy, KYZATREX® (CIII testosterone undecanoate capsules) on Male Fertility
January 9, 2024
Marius Pharmaceuticals Announces Pilot Study Exploring the Effect of Its Oral Testosterone Therapy, KYZATREX® (CIII testosterone undecanoate capsules), on Male Fertility Raleigh, N.C.,…Read more
Marius Pharmaceuticals Announces KYZATREX® (CIII testosterone undecanoate capsules) HERO Campaign, Empowering Men to ‘Be the Hero of Your Life Again
December 6, 2023
Media Contact:5W Public Relationskyzatrex@5wpr.com212-999-5585 Marius Pharmaceuticals Announces KYZATREX® (CIII testosterone undecanoate capsules) HERO Campaign, Empowering Men To ‘Be the Hero of Your…Read more
Marius Pharmaceuticals Expands Access of KYZATREX™ (testosterone undecanoate) to Department of Veterans Affairs (VA), Pledging Support for Proper Hormonal Balance Among Military Personnel
September 9, 2023
Marius Pharmaceuticals Expands Access of KYZATREX™ (testosterone undecanoate) to Department of Veterans Affairs (VA), Pledging Support for Proper Hormonal Balance Among Military…Read more
Marius Pharmaceuticals Partners with Smartway to Design and Manage the Global Early Access Program for KYZATREX™ (testosterone undecanoate)
August 10, 2023
Marius Pharmaceuticals Partners with Smartway to Design and Manage the Global Early Access Program for KYZATREX™ (testosterone undecanoate) RALEIGH, N.C., August…Read more
Marius Pharmaceuticals Announces Launch of ReThink Testosterone, Disease-State Awareness Initiative for Patients
July 24, 2023
Marius Pharmaceuticals Announces Launch of ReThink Testosterone, Disease-State Awareness Initiative for Patients RALEIGH, N.C. July 24, 2023 – Marius Pharmaceuticals,…Read more
Marius Pharmaceuticals Supports AXYS 2023 Virtual Family Conference, Spotlighting KYZATREX™ for XY Chromosome Variations, such as Klinefelter’s Syndrome
June 20, 2023
Marius Pharmaceuticals Supports AXYS 2023 Virtual Family Conference, Spotlighting KYZATREX™ for XY Chromosome Variations, such as Klinefelter’s Syndrome RALEIGH, N.C.,…Read more
Marius Pharmaceutical Announces Two Key Patents Related to KYZATREX™ in FDA Orange Book
June 9, 2023
Marius Pharmaceuticals Announces Two Key Patents Related to KYZATREX™ in FDA Orange Book RALEIGH, N.C., June 9, 2023 – Marius Pharmaceuticals,…Read more
Marius Pharmaceuticals Receives FDA Approval of KYZATREX™, an Oral Testosterone Replacement Therapy
August 2, 2022
Marius Pharmaceuticals Receives FDA Approval of KYZATREX™, an Oral Testosterone Replacement Therapy August 2, 2022 RALEIGH, N.C. August 2, 2022…Read more
Marius Announces Ambulatory Blood Pressure Results Published in the Journal of Clinical Hypertension with their new testosterone medication KYZATREX™
June 11, 2021
Marius Announces Ambulatory Blood Pressure Results Published in the Journal of Clinical Hypertension with their new testosterone medication KYZATREX™ RALEIGH,…Read more
Marius Pharmaceuticals Announces Co-CEOs Himanshu H. Shah and Shalin Shah to Drive Growth ahead of Anticipated FDA Action of its Lead Asset, KYZATREX™
January 27, 2021
MARIUS PHARMACEUTICALS ANNOUNCES CO-CEOS HIMANSHU H. SHAH AND SHALIN SHAH TO DRIVE GROWTH AHEAD OF ANTICIPATED FDA ACTION OF ITS…Read more
Marius Pharmaceuticals Announces Issuance of Two Key Patents Protecting its Proprietary Oral Testosterone Therapy
May 21, 2020
MARIUS PHARMACEUTICALS ANNOUNCES ISSUANCE OF TWO KEY PATENTS PROTECTING ITS PROPRIETARY ORAL TESTOSTERONE THERAPY RALEIGH, N.C., May 21, 2020 (GLOBE…Read more
Booking Information
Interested in having Shalin Shah speak at your next event?
Contact us to check availability: info@mariuspharma.com
Booking Form
"*" indicates required fields
Use
KYZATREX® (testosterone undecanoate) is a prescription drug that is used to treat adult men who have low or no testosterone levels due to certain medical conditions.
KYZATREX is a controlled substance (CIII) because it contains testosterone. It is not known if KYZATREX is safe or effective in males younger than 18 years old. Improper use may affect bone growth in children. KYZATREX is not meant for use by women.
IMPORTANT SAFETY INFORMATION FOR KYZATREX®
KYZATREX can increase blood pressure, which can increase the risk of having a heart attack or stroke and can increase risk of death due to a heart attack or stroke. Your risk may be greater if you have already had a heart attack or stroke or if you have other risk factors for heart attack or stroke.
- If your blood pressure increases while on KYZATREX, blood pressure medicines may need to be started. If you are currently taking blood pressure medicines, they may need to be changed or new blood pressure medicines may need to be added to control your blood pressure.
- If your blood pressure cannot be controlled, KYZATREX may need to be stopped.
- Your healthcare provider will monitor your blood pressure while you are being treated with KYZATREX.
Do not take KYZATREX if you: have breast cancer; have or might have prostate cancer; are a woman who is pregnant (KYZATREX may harm your unborn baby); are allergic to KYZATREX or any of its ingredients; or have low testosterone without certain medical conditions (e.g., do not take KYZATREX if you have low testosterone due to age).
Before you take KYZATREX, tell your healthcare provider about all of your medical conditions, including if you: have high blood pressure or are treated for high blood pressure; have a history of diabetes; have heart problems; have high red blood cell count (hematocrit) or high hemoglobin laboratory value; have urinary problems due to an enlarged prostate; have liver or kidney problems; or have problems breathing while you sleep (sleep apnea).
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking KYZATREX with certain other medicines can affect each other. Especially, tell your healthcare provider if you take: insulin; medicines that decrease blood clotting (blood thinners); corticosteroids; or medicines that increase blood pressure, such as some cold medicine and pain medicines.
KYZATREX may cause other serious side effects including:
- Increase in red blood cell count (hematocrit) or hemoglobin, which can increase the risk of blood clots, strokes, and heart attacks. You may need to stop KYZATREX if your red blood cell count increases.
- If you already have an enlarged prostate, your signs and symptoms may worsen while taking KYZATREX. These may include: increased urination at night; trouble starting your urine stream; urinating many times during the day; urge to go to the bathroom right away; a urine accident; inability to pass urine or weak urine flow.
- Increased risk of prostate cancer.
- Blood clots in the legs or lungs. Signs and symptoms of a blood clot in your leg can include pain, swelling or redness. Signs and symptoms of a blood clot in your lungs can include difficulty breathing or chest pain.
- Abuse. Testosterone can be abused when taken at higher than prescribed doses and when used with other anabolic androgenic steroids. Abuse can cause serious heart and psychological side effects.
- In large doses, KYZATREX may lower your sperm count.
- Liver problems. Symptoms of liver problems may include: nausea or vomiting; yellowing of your skin or whites of your eyes; dark urine; pain on the right side of your stomach area (abdominal pain).
- Swelling of your ankles, feet, or body (edema), with or without heart failure.
- Enlarged or painful breasts.
- Breathing problems while you sleep (sleep apnea).
Call your healthcare provider right away if you have any of the serious side effects listed above.
The most common side effect of KYZATREX is high blood pressure. Other side effects may include: headache, joint or back pain, diarrhea, increased red blood cell count, anxiety, constipation, swelling of the legs, and increased prostate specific antigen (PSA) levels.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Marius by visiting www.mariuspharma.com.
These are not all the possible side effects of KYZATREX. For more information, ask your healthcare provider or pharmacist.
Keep KYZATREX and all medicines out of the reach of children.